Clinical trials: Anastrozole
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.
This study is a multicenter, international, open-label phase II study. Based on inclusion/exclusion criteria, eligible pre and postmenopausal patients with newly diagnosed metastatic luminal hormone receptor-positive and HER2…
- Trial name
- ICRG0201 (NCT05190094)
- Testing
- Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)
- Where
- 7 sites in Algeria, Jordan and 1 more
- Volunteers
- 80 people
- Sponsor
- International Cancer Research Group, United Arab Emirates
Puberty, Precocious
Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]
The primary objective of this study is to investigate whether bicalutamide given in combination with anastrozole once daily for 12 months is effective in treating testotoxicosis in boys.
- Trial name
- BATT (NCT00094328)
- Testing
- Bicalutamide, Anastrozole
- Where
- 15 sites in United States, Canada and 4 more
- Volunteers
- 14 people
- Sponsor
- AstraZeneca
Hypertension
Testosterone Regulation of the Natriuretic Peptide System
The proposed study is a physiologic investigation of the effects of testosterone on the natriuretic peptide system. The hypotheses of the study are that testosterone administration will decrease natriuretic peptide levels and…
- Trial name
- NCT02269072
- Testing
- Testosterone, Nesiritide, Leuprolide
- Volunteers
- healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Inguinal Hernia Unilateral, Inguinal Hernia Bilateral
Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males
This is a prospective, single-center, two-arm Phase 1 safety and feasibility trial evaluating anti-estrogen therapy in men age 50 years and older with symptomatic unilateral inguinal hernias.
- Conditions
- Inguinal Hernia Unilateral, Inguinal Hernia Bilateral, Inguinal Hernia Without Obstruction or Gangrene, Inguinal Hernia, Without Mention of Obstruction or Gangrene
- Trial name
- RIGHT (NCT07604272)
- Testing
- Fulvestrant, Anastrozole (ARIMIDEX™)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
Breast Cancer
Retrospective Analysis of Effectiveness and Safety Profile of Anastrozole and Letrozole in HR+ Breast Cancer Patients
This is a single centre, observational and retrospective clinical study. The study group was about all HR positive postmenopausal breast cancer patients who were hospitalized between January, 2008 and October, 2010, and ever…
- Trial name
- NCT02812277
- Volunteers
- 1,000 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Breast Cancer
Detect V / CHEVENDO (Chemo vs. Endo)
Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive…
- Trial name
- NCT02344472
- Testing
- pertuzumab, Trastuzumab, Capecitabine
- Where
- Germany
- Volunteers
- 271 people
- Sponsor
- Prof. Wolfgang Janni
Breast Cancer, Hormone Receptor Positive Tumor
Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
This study is to find out if an investigational drug called Durvalumab (MEDI4736) given together with a standard of care aromatase inhibitor drug can help people with breast cancer.
- Trial name
- NCT03874325
- Testing
- Durvalumab, Anastrozole 1mg, Letrozole 2.5mg
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic ER+ Her2- Breast Cancer, Postmenopausal
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
The purpose of this study is to assess the safety and efficacy of oral abiraterone acetate plus oral prednisone and oral abiraterone acetate plus oral prednisone plus oral exemestane, each compared with oral exemestane alone, in…
- Trial name
- NCT01381874
- Testing
- Exemestane, Abiraterone acetate + Prednisone/ Prednisolone + Exemestane, Abiraterone acetate + Prednisone or Prednisolone
- Where
- 81 sites in United States, Belgium and 10 more
- Volunteers
- 297 people
- Sponsor
- Janssen Research & Development, LLC
Breast Cancer, Solid Tumors, Adult
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid…
- Trial name
- PIKALO-1 (NCT05768139)
- Testing
- STX-478, Fulvestrant, Ribociclib
- Where
- 65 sites in United States, Belgium and 7 more
- Volunteers
- 880 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.
The purpose of this study is to assess the difference in event-free survival between postmenopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued to…
- Trial name
- NCT00291759
- Testing
- Tamoxifen, Anastrozole
- Where
- 52 sites in Austria
- Volunteers
- 3,858 people
- Sponsor
- AstraZeneca
Breast Cancer
ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years
The purpose of this study was to assess the difference in disease-free survival between post-menopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued…
- Trial name
- NCT00286117
- Testing
- Anastrozole, Tamoxifen
- Where
- 25 sites in Italy
- Volunteers
- 448 people
- Sponsor
- AstraZeneca
Breast Cancer
Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer
The primary objective of this study is to compare progression-free survival (PFS) of patients with metastatic Luminal B2 breast cancer subtype randomised to treatment with Trastuzumab Combined With Chemotherapy or Endocrine…
- Trial name
- SYSUCC-002 (NCT01950182)
- Testing
- Endocrine therapy combined with trastuzumab, Chemotherapy combined with trastuzumab
- Where
- China
- Volunteers
- 392 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia
This prospective, observational, multicenter study aims at evaluating the efficacy of adjuvant ribociclib in combination with hormone therapy (aromatase inhibitor ± GnRH aginost) in various subgroups of patients with HR+HER2…
- Trial name
- ELEGANCE (NCT06930859)
- Testing
- Ribociclib, Letrozole, Anastrozole
- Where
- 42 sites in Russia
- Volunteers
- 2,766 people
- Sponsor
- Novartis Pharmaceuticals
Estrogen Receptor Positive, HER2/Neu Negative
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer
This phase II trial studies how well Akt inhibitor MK-2206 (MK-2206) and anastrozole with or without goserelin acetate works in treating patients with stage II-III breast cancer.
- Conditions
- Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma, Stage IIA Breast Cancer
- Trial name
- NCT01776008
- Testing
- Akt Inhibitor MK2206, Anastrozole, Goserelin Acetate
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients
This study compared long term outcome of stage IIIB/C and IV breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy (NACT)
- Trial name
- NCT02995772
- Testing
- Aromatase Inhibitors (Arimidex), Tamoxifen, SOB
- Where
- Indonesia
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Dharmais National Cancer Center Hospital
Advanced Breast Cancer
A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
This is a phase III clinical trial to evaluate the efficacy and safety of SHR6390 in combination with Letrozole or Anastrozole versus placebo in combination with Letrozole or Anastrozole in Patients who have HR positive and HER2…
- Trial name
- NCT03966898
- Testing
- SHR6390 Tablets, Letrozole or Anastrozole Tablets
- Where
- China
- Volunteers
- 426 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Ductal Carcinoma in Situ, Extensive Disease
Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ
Ductal carcinoma in situ (DCIS) accounts for approximately 20% of newly diagnosed breast cancer cases. Of these women, 20% require radical management in the form of mastectomy because of the extent of the lesions, which most…
- Conditions
- Ductal Carcinoma in Situ, Extensive Disease, Mastectomy
- Trial name
- HORNEO01 (NCT04666961)
- Testing
- Tamoxifen 20 mg, Anastrozole 1Mg Tab
- Where
- 8 sites in France
- Volunteers
- 262 people
- Sponsor
- Institut Cancerologie de l'Ouest
HER2/Neu Negative, Invasive Breast Carcinoma
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
This pilot clinical trial studies how well endocrine therapy works in treating patients with HER2 negative, low risk breast cancer. Estrogen can cause the growth of breast cancer cells.
- Conditions
- HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal, Stage 0 Breast Cancer
- Trial name
- NCT03238703
- Testing
- Anastrozole, Exemestane, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer
Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database
The purpose of this project is to establish a repository of information and samples from breast cancer patients or those at high risk of developing breast cancer, who are initiating hormone therapy as part of standard clinical…
- Trial name
- NCT01937052
- Testing
- Sample collection, Patient-reported outcomes
- Where
- United States
- Volunteers
- 329 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ER+ HER2- Advanced Breast Cancer
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women with ER Positive, HER2 Negative Advanced Breast Cancer (SERENA-1)
- Trial name
- SERENA-1 (NCT03616587)
- Testing
- AZD9833, AZD9833 with palbociclib, AZD9833 with everolimus
- Where
- 17 sites in United States, Spain and 1 more
- Volunteers
- 396 people
- Sponsor
- AstraZeneca